E-Table 1.
Comparison of prognostic variables*
| Clinical variable | Study cohort | Comparative cohort | p-value |
|---|---|---|---|
| Age | 70.3 (8.7) | 73.8 (9.7) | 0.99 |
| Female, n (%) | 24 (49.0) | 218 (56.0) | 0.35 |
| Race, n (%) | 0.77 | ||
| African American | 9 (18.4) | 44 (12.8) | |
| Caucasian | 39 (79.6) | 305 (84.3) | |
| Pack-years | 50.0 (28.7) | 56.3 (39.8) | 0.23 |
| CCI, n (%) | 0.69 | ||
| 0-2 | 26 (60.5) | 212 (54.3) | |
| 3-6 | 17 (39.5) | 177 (45.4) | |
| KPS | 81.2 (9.3) | 78.1 (10.0) | 0.06 |
| Tumor size, cm | 2.8 (1.4) | 2.5 (1.3) | 0.12 |
| SUV | 10.4 (7.3) | 9.5 (6.8) | 0.17 |
| FEV1, % predicted | 59.8 (20.0) | 65.7 (56.8) | 0.90 |
| DLCO, % predicted | 44.5 (18.3) | 55.1 (19.8) | 1.00 |
| Histology, n (%) | 0.27 | ||
| Adenocarcinoma | 17 (34.7) | 96 (25.1) | |
| Squamous cell carcinoma | 13 (26.5) | 111 (29.0) | |
| Small cell carcinoma | 2 (4.1) | 7 (1.8) | |
| Non-diagnostic/never-biopsied | 17 (34.7) | 131 (34.2) | |
| Clinical stage | 0.62 | ||
| Ia | 37 (75.5) | 268 (68.9) | |
| Ib | 8 (16.3) | 90 (23.1) | |
| IIa | 4 (8.2) | 21 (5.4) |
6MWD = 6-minute walk distance; 6MWT = 6-minute walk test; BDS = Borg dyspnea score; BMI = body-mass index; CCI = Charlson comorbidity index; DBP = diastolic blood pressure; DLCO = diffusion capacity of carbon monoxide; FEV1 = forced expiratory volume within 1 second; HR = heart rate; HRR = heart rate recovery; KPS = Karnofsky performance status; LLL = left lower lobe; LUL = left upper lobe; RLL = right lower lobe; RML = right middle lobe; RUL = right upper lobe; SBP = systolic blood pressure; SUV = standardized uptake value
The 49 patients in the study cohort were compared to 389 other patients receiving SBRT within the same time period for early-stage lung cancer.
Values are expressed as means and standards of deviations, unless specified